miR-155 could then be passaged back to the tumor cells via EVs downregulating the miR-155 target telomeric repeat binding factor 1 (TERF1), a telomerase inhibitor, with subsequent upregulation of telomerase which promotes neuroblastoma drug resistance [117]. Here, TERF1 is linked to neoplasm.